Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/10/2025 | $23.50 | Neutral | Redburn Atlantic |
3/24/2025 | $25.00 | In-line | Evercore ISI |
1/6/2025 | $21.00 → $26.00 | Neutral → Overweight | Piper Sandler |
12/12/2024 | $25.00 → $24.00 | Buy → Hold | Deutsche Bank |
9/24/2024 | $27.00 | Buy | Jefferies |
9/24/2024 | $24.00 | Outperform → Sector Perform | RBC Capital Mkts |
5/28/2024 | $21.00 | Neutral | Citigroup |
4/11/2024 | $18.00 | Underperform | Bernstein |
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
4 - Kenvue Inc. (0001944048) (Issuer)
3 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
Kenvuers contribute 5,000+ hours of volunteer time to local causes along with building 22,000+ hygiene kits for underserved communities Hygiene kits to feature 110,000+ donated products from iconic brands Neutrogena®, Listerine®, OGX®, Johnson's® Baby and more Kenvue Inc. (NYSE:KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced its global community engagement efforts in celebration of Kenvue Cares Week, the company's signature annual volunteer initiative part of its Healthy Lives Mission. Kenvue Cares Week is a testament to the strong Kenvue commitment to advance the well-being of people and our planet, giving back through voluntee
Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p
Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation
Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50
Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00
Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously
Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation
Company and Starboard Value LP Enter into Cooperation Agreement Kenvue Inc. (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the appointment of two new independent directors, Sarah Hofstetter, President of Profitero, Ltd., and Erica Mann, former President and Head of Bayer's Consumer Health Division, to the Company's Board of Directors (the "Board"). Additionally, Jeffrey Smith, Managing Member, Chief Executive Officer and Chief Investment Officer of Starboard Value LP (together with certain of its affiliates, "Starboard") will join the Board. All three appointments are effective immediately. "We are pleased to welcome Sarah, Erica and Jeff as
Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa
SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)
SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)
10-Q - Kenvue Inc. (0001944048) (Filer)
Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p
Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine
Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in